A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Diagnostic use
- Acronyms LYMRIT-37-02
- Sponsors Nordic Nanovector
- 11 Apr 2017 Planned number of patients changed from 12 to 8.
- 11 Apr 2017 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.
- 11 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.